Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review.
COVID-19
Coronavirus
Pneumonia
SARS-CoV-2
Tocilizumab
Journal
Pulmonology
ISSN: 2531-0437
Titre abrégé: Pulmonology
Pays: Spain
ID NLM: 101723786
Informations de publication
Date de publication:
Historique:
received:
06
07
2020
accepted:
07
07
2020
pubmed:
28
7
2020
medline:
13
1
2021
entrez:
28
7
2020
Statut:
ppublish
Résumé
Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety. MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020. We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group, 15 single-arm). To date, no randomized trials have been published. We retrieved no studies at low risk of bias. Forty-five ongoing studies were retrieved from trial registries. There is insufficient evidence regarding the clinical efficacy and safety of tocilizumab in patients with COVID-19. Its use should be considered experimental, requiring ethical approval and clinical trial oversight.
Sections du résumé
BACKGROUND
BACKGROUND
Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety.
METHODS
METHODS
MEDLINE, PubMed, EMBASE, pre-print repositories (bioRxiv and medRxiv) and two trial Registries were searched for studies on the use of tocilizumab in COVID-19 or SARS-CoV-2 infection, viral pneumonia, and/or sepsis until 20th June 2020.
RESULTS
RESULTS
We identified 3 indirect pre-clinical studies and 28 clinical studies including 5776 patients with COVID-19 (13 with a comparison group, 15 single-arm). To date, no randomized trials have been published. We retrieved no studies at low risk of bias. Forty-five ongoing studies were retrieved from trial registries.
CONCLUSIONS
CONCLUSIONS
There is insufficient evidence regarding the clinical efficacy and safety of tocilizumab in patients with COVID-19. Its use should be considered experimental, requiring ethical approval and clinical trial oversight.
Identifiants
pubmed: 32713784
pii: S2531-0437(20)30153-7
doi: 10.1016/j.pulmoe.2020.07.003
pmc: PMC7369580
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
IL6 protein, human
0
Interleukin-6
0
tocilizumab
I031V2H011
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
52-66Commentaires et corrections
Type : CommentIn
Type : CommentIn
Type : CommentIn
Informations de copyright
Copyright © 2020 Sociedade Portuguesa de Pneumologia. Published by Elsevier España, S.L.U. All rights reserved.
Références
Autoimmun Rev. 2020 Jul;19(7):102568
pubmed: 32376398
Clin Exp Rheumatol. 2020 May-Jun;38(3):529-532
pubmed: 32359035
Microorganisms. 2020 May 09;8(5):
pubmed: 32397399
Lancet Rheumatol. 2020 Aug;2(8):e474-e484
pubmed: 32835257
Clin Infect Dis. 2021 Jul 15;73(2):e445-e454
pubmed: 32651997
PLoS One. 2020 Aug 13;15(8):e0237693
pubmed: 32790733
J Immunol. 2019 Jan 15;202(2):484-493
pubmed: 30530483
Ann Rheum Dis. 2020 Jun;79(6):760-770
pubmed: 32033941
Pharmazie. 2016 Nov 2;71(11):636-639
pubmed: 29441967
J Clin Virol. 2020 Aug;129:104444
pubmed: 32570043
Rev Med Virol. 2020 Nov;30(6):1-9
pubmed: 32845568
Clin Microbiol Infect. 2021 Feb;27(2):238-243
pubmed: 32979572
Cell Death Differ. 2020 May;27(5):1451-1454
pubmed: 32205856
Eur J Intern Med. 2020 Jun;76:21-22
pubmed: 32425364
Cochrane Database Syst Rev. 2010 Jul 07;(7):CD008331
pubmed: 20614469
Crit Care. 2020 May 8;24(1):210
pubmed: 32384908
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
J Med Virol. 2020 Oct;92(10):2042-2049
pubmed: 32369191
Inflammopharmacology. 2020 Feb;28(1):215-230
pubmed: 31440860
Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
Eur J Intern Med. 2020 Jun;76:36-42
pubmed: 32448770
Clin Transl Sci. 2021 Nov;14(6):2146-2151
pubmed: 32918792
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
J Med Virol. 2020 Jul;92(7):814-818
pubmed: 32253759
Pathog Immun. 2020 Oct 02;5(1):327-341
pubmed: 33089038
J Transl Med. 2020 Oct 21;18(1):405
pubmed: 33087150
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Hum Vaccin Immunother. 2017 Sep 2;13(9):1972-1988
pubmed: 28841363
Front Med (Lausanne). 2020 Oct 28;7:583897
pubmed: 33195334
Lancet. 1998 Mar 28;351(9107):929-33
pubmed: 9734938
EClinicalMedicine. 2020 Jun 20;24:100418
pubmed: 32766537
JAMA. 2020 Feb 25;323(8):713-715
pubmed: 32065830
Res Synth Methods. 2021 Jan;12(1):55-61
pubmed: 32336025
BMJ. 2016 Oct 12;355:i4919
pubmed: 27733354
Eur J Intern Med. 2020 Jun;76:31-35
pubmed: 32405160
Intensive Care Med. 2020 Aug;46(8):1590-1593
pubmed: 32504103
J Exp Med. 1994 Apr 1;179(4):1253-9
pubmed: 8145042
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
N Engl J Med. 2012 Dec 20;367(25):2385-95
pubmed: 23252525
Pharmaceuticals (Basel). 2020 Oct 17;13(10):
pubmed: 33080877
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
JAMA. 2020 May 12;323(18):1824-1836
pubmed: 32282022
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Thromb Haemost. 1996 Nov;76(5):738-42
pubmed: 8950783
Chest. 2020 Oct;158(4):1397-1408
pubmed: 32553536
Eur J Intern Med. 2020 Jun;76:43-49
pubmed: 32482597
Clin Drug Investig. 2020 Jun;40(6):511-518
pubmed: 32337664